- Trial phase
- Preclinical (IND cleared for Phase 1/2)
- Time to market
- Unknown, the drug is in late-stage preclinical development with an IND cleared for an NCI-led Phase 1/2 trial. Even if the trial begins soon, clinical development typically takes 5+ years for a novel immunotherapy.
- Why 1/10
- No hard, dated catalyst is scheduled for PDS0103 in the next ~12 months. The drug is preclinical/IND-stage, the company has deprioritized it in favor of PDS0301, and the NCI-led Phase 1/2 trial has no publicly announced enrollment or data-readout timeline. ImpactScore is 1 because PDS0103 is a very early-stage, deprioritized program at a cash-constrained company with no near-term binary event.
PDS0103 is a preclinical/IND-stage asset that has been deprioritized by PDS Biotech in favor of PDS0301. The NCI-led Phase 1/2 trial could begin enrollment at any time, but the company has no near-term catalyst for this drug and is actively seeking a partner for the Versamune platform. Watch for partnership announcements or NCI trial initiation as potential value-unlocking events, but the stock's near-term trajectory depends almost entirely on PDS0301 developments.
Price Chart
Executive Summary
PDS0103 (Versamune MUC1) is an early-stage, preclinical cancer immunotherapy from PDS Biotechnology Corp (Nasdaq: PDSB) that targets MUC1-positive solid tumors. The FDA cleared an IND in March 2025 for an NCI-led Phase 1/2 trial in metastatic colorectal cancer, but no human data or enrollment updates have been reported. In August 2026, PDS Biotech announced a strategic refocus prioritizing PDS0301 (an IL-12 immunocytokine) and stated it would seek partnerships for the Versamune platform, meaning PDS0103 is now a deprioritized, non-core asset at a company with only ~$5.6M in cash. With no near-term catalysts and no clinical data, PDS0103 is a very minor component of PDSB's investment thesis.
How It Works
PDS0103 is a cancer vaccine that trains the body's immune system to recognize and attack cells displaying a protein called MUC1, which is found on the surface of many solid tumors (including breast, ovarian, colorectal, and lung cancers). It uses PDS Biotech's Versamune® platform, a synthetic molecule that activates T cells (the immune system's killer cells), combined with MUC1 protein fragments designed by the National Cancer Institute. The drug is given as a simple shot under the skin.
Trial Status
PDS0103 is in late-stage preclinical development. The FDA cleared an IND application in March 2025 for a Phase 1/2 trial evaluating PDS0103 (Versamune MUC1) in combination with PDS01ADC for metastatic colorectal cancer, to be conducted by the National Cancer Institute under a CRADA. No enrollment or data updates have been announced as of October 2026.
The Two-Sided Case
Upcoming Catalysts
- Potential initiation of NCI-led Phase 1/2 trial (no timeline announced)
- Possible Versamune platform partnership announcement (company seeking external funding for all Versamune assets)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PDS Biotechnology Corp 8-K PDSB ·Originating report